Batavia Biosciences Increases Capacity for Viral Vectors and Vaccine R&D in the Netherlands

News
Article

Batavia Biosciences is expanding its headquarters and R&D capabilities in its Netherlands facility.

Batavia Biosciences announced the expansion of its headquarters and R&D capacity in its Netherlands facility on June 14, 2022. The 22,500-ft² expansion will increase R&D activities for viral vector-based product development, including Lentivirus, adeno-associated virus (AAV), adenovirus, and measles virus vectors. The expansion is expected to be finalized by June 2023.

“The new laboratory floor space for R&D and analytical capabilities will aid the development capacity for customer projects,” said Chris Yallop, chief scientific officer, Batavia Biosciences, in a company press release. “The increased allocation for R&D capacity better positions Batavia Biosciences to serve as pacemakers to the community and to continue to bring promising candidate biopharmaceuticals from bench to clinic.”

According to a company press release, the increased R&D infrastructure is intended to meet increased global development for vaccine development, including live-attenuated, whole killed, vectored, or subunit vaccines.

Source: Batavia Biosciences

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content